NovoCure (NVCR) Non-Current Assets (2014 - 2026)

NovoCure has disclosed Non-Current Assets across 13 years of filings, most recently posting $156.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $156.3 million, down 2.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $156.3 million (down 2.03% YoY), and the FY2025 annual result was $157.6 million, up 17.43% from the prior year.
• Non-Current Assets came in at $156.3 million for Q1 2026 at NovoCure, down from $157.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $162.6 million in Q2 2025 to a low of $68.1 million in Q2 2022.
• The 5-year median for Non-Current Assets is $118.7 million (2024), against an average of $116.2 million.
• Across the five-year window, Non-Current Assets surged 39.64% in 2022 and dropped 2.03% in 2026, its largest moves.
• NovoCure's Non-Current Assets stood at $80.1 million in 2022, then surged by 39.44% to $111.7 million in 2023, then advanced by 20.13% to $134.2 million in 2024, then gained by 17.43% to $157.6 million in 2025, then retreated by 0.85% to $156.3 million in 2026.
• The last three Non-Current Assets figures came in at $156.3 million (Q1 2026), $157.6 million (Q4 2025), and $161.3 million (Q3 2025), per Business Quant data.